Holen Sie sich die Stockscreener-App
40.68
1.02%
-0.42
Vorhandelsmarkt:
40.45
-0.23
-0.57%
Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten
Crinetics earnings on deck: Can drug launch offset mounting losses? By Investing.com - Investing.com South Africa
JPMorgan Chase & Co. Grows Stake in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
US Market Recap: Should value investors consider Crinetics Pharmaceuticals Inc2025 Price Momentum & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Preview: Crinetics Pharmaceuticals's Earnings - Benzinga
Crinetics Pharmaceuticals, Inc. (CRNX) Stock Analysis: A Potential 94% Upside Lures Investors - DirectorsTalk Interviews
Is Crinetics Pharmaceuticals (CRNX) Offering Value After Recent Share Price Pullback - Yahoo Finance
Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight - StreetInsider
Crinetics Pharmaceuticals, Inc. $CRNX Shares Purchased by Skandinaviska Enskilda Banken AB publ - MarketBeat
Aberdeen Group plc Has $14.16 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Market Recap: What is the next catalyst for BTCTJuly 2025 Intraday Action & High Conviction Buy Zone Alerts - baoquankhu1.vn
Setup Watch: Should value investors consider Crinetics Pharmaceuticals IncJuly 2025 Technicals & Short-Term Swing Trade Alerts - baoquankhu1.vn
Crinetics Pharmaceuticals (CRNX) Expected to Announce Earnings on Thursday - MarketBeat
Analysts Bullish on Crinetics (CRNX) Amid Positive Clinical Trial for New Drug - Insider Monkey
Market Catalysts: Whats the beta of Crinetics Pharmaceuticals Inc stockJuly 2025 Volume & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
13 Hot Stocks to Buy with the Highest Upside Potential - Insider Monkey
Crinetics Pharmaceuticals, Inc. (CRNX): Investor Outlook With A 99% Potential Upside - DirectorsTalk Interviews
Crinetics Pharmaceuticals announces $350M proposed public offering - MSN
New Highs: Can Crinetics Pharmaceuticals Inc be recession proofEntry Point & Growth Oriented Trade Recommendations - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Abbott Laboratories (ABT) - The Globe and Mail
Crinetics Pharmaceuticals (NASDAQ:CRNX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Candriam S.C.A. Grows Stock Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharmaceuticals, Inc. (CRNX) Investor Outlook: An 82.74% Potential Upside Drives Market Interest - DirectorsTalk Interviews
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Liquidity Mapping Around (CRNX) Price Events - Stock Traders Daily
Recap Report: Is RSSS affected by consumer sentimentJuly 2025 WrapUp & Target Return Focused Stock Picks - baoquankhu1.vn
Weekly Recap: Is Crinetics Pharmaceuticals Inc exposed to currency risksPortfolio Performance Report & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March - GlobeNewswire
Recap Report: Is Crinetics Pharmaceuticals Inc exposed to currency risksPortfolio Growth Summary & High Conviction Buy Zone Alerts - baoquankhu1.vn
Crinetics Pharmaceuticals, Inc. (CRNX): Investor Outlook On Its 70% Upside Potential - DirectorsTalk Interviews
Analysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Stryker (SYK) - The Globe and Mail
Lisanti Capital Growth LLC Purchases New Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Momentum Shift: Can Crinetics Pharmaceuticals Inc. stock outperform in a bear marketWeekly Trend Recap & Safe Entry Trade Reports - baoquankhu1.vn
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - The Manila Times
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Share Price Volatility - Yahoo Finance
Crinetics Pharmaceuticals updates Jeff Knight’s executive title and responsibilities By Investing.com - Investing.com Nigeria
Crinetics Pharmaceuticals updates Jeff Knight’s executive title and responsibilities - Investing.com
Why (CRNX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Pullback Watch: Is Crinetics Pharmaceuticals Inc exposed to currency risks2025 Trade Ideas & Community Verified Trade Alerts - baoquankhu1.vn
Jim Cramer on Crinetics: “That’s a better spec than Aquestive” - MSN
Crinetics Pharmaceuticals, Inc. $CRNX Stock Holdings Boosted by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Crinetics Starts Pediatric BALANCE CAH Trial As Valuation Gap Persists - Sahm
Crinetics begins phase 2/3 trial of oral CAH treatment in children - Investing.com Nigeria
Crinetics (CRNX) Launches Phase 2/3 Trial for Atumelnant in Pedi - GuruFocus
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH) - The Manila Times
Jim Cramer on Crinetics: “That’s a Better Spec Than Aquestive” - Insider Monkey
Is It Too Late To Consider Crinetics Pharmaceuticals (CRNX) After Strong Multi‑Year Share Gains? - Sahm
Goldman Sachs upgrades Crinetics Pharmaceuticals, Inc. (CRNX) to buy from neutral - MSN
A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Goldman Sachs Upgrade And Palsonify Atumelnant Progress - Sahm
Retail Surge: What is the dividend yield of Crinetics Pharmaceuticals Inc2025 Analyst Calls & Fast Gaining Stock Reports - baoquankhu1.vn
Crinetics Pharmaceuticals exec sells shares worth $195,350 - MSN
2.90%
2.73%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):